$0.58
-0.04 (-6.63%)
Open$0.60
Previous Close$0.62
Day High$0.60
Day Low$0.57
52W High$5.75
52W Low$0.60
Volume—
Avg Volume222.3K
Market Cap20.63M
P/E Ratio—
EPS$-1.41
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,655.6% upside
Current
$0.58
$0.58
Target
$15.90
$15.90
$11.92
$15.90 avg
$19.90
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.64M | 3.84M | 3.77M |
| Net Income | 720.4K | 800.4K | 930.4K |
| Profit Margin | 19.8% | 20.8% | 24.7% |
| EBITDA | 1.38M | 1.54M | 1.32M |
| Free Cash Flow | 559.4K | 545.0K | 561.2K |
| Rev Growth | +15.7% | +20.7% | +9.8% |
| Debt/Equity | 0.34 | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |